GSK reaches agreement to acquire late-stage biopharmaceutical …
2023年4月18日 · The acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line …
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
2025年1月19日 · Camlipixant is under clinical development by GSK and currently in Phase III for Chronic Cough. According to GlobalData, Phase III drugs for Chronic Cough have a 50% …
GSK completes acquisition of BELLUS Health
2023年6月28日 · As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development …
After Merck's cough drama, GSK knew what to do with Bellus asset
2023年11月30日 · Now, after closing the $2 billion deal in June, GSK is showcasing the phase 3 camlipixant program and ready to replace Merck as the market leader. Two studies called …
GSK inks $2B Bellus buyout to challenge Merck for cough market
2023年4月18日 · Bellus’ lead candidate is camlipixant, a molecule with the same mechanism of action as gefapixant. Both drugs are antagonists of P2X3, a peripheral nervous system …
GSK buys purine receptor antagonist for $2 billion - Nature
2023年5月10日 · GSK has acquired BELLUS Health to secure rights to camlipixant, signalling continued interest in P2X purinoceptor 3 (P2X3) antagonists for refractory chronic cough.
GSK Makes $2B Play to Challenge Merck in Chronic Cough Market
2023年4月18日 · Tuesday, GSK signed an acquisition agreement with Bellus Health for $2 billion to gain access to the Canadian biotech’s chronic cough candidate camlipixant. GSK will …
GSK bolsters respiratory pipeline with Bellus Health buy
2025年3月25日 · The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready …
GSK to buy Bellus Health and its chronic cough drug for $2B
2023年4月18日 · Bellus’ drug, called camlipixant, is currently being tested in two Phase 3 studies of people with persistent cough that either doesn’t have a clear cause or can’t be relieved by …
GSK Inks $2 Billion For Cough Medicine Biotech To Bolster Drug ... - Forbes
2023年4月18日 · The drug, camlipixant, is undergoing late-stage clinical trials and has shown promise against refractory chronic cough, a persistent and sometimes debilitating condition …